Skip directly to search Skip directly to A to Z list Skip directly to the left nav Skip directly to the table data Skip directly to the reports section
CDC Antibiotic Resistance Investment Map
CDC's strategic investments empower the nation to combat antibiotic resistance (AR), the global threat jeopardizing modern medicine. The Fiscal Year 2016 investments shown here support comprehensive, coordinated, and ambitious public health action to meet national goals to prevent drug-resistant infections. Learn more about CDC’s work to combat AR.

Looking for funding information about Fiscal Year 2017? Go to the Antibiotic Resistance Solutions Initiative page.

Learn more about CDC activities to combat antibiotic resistance.


Local health department that received additional funding.
Location of one of seven ARLN regional labs.
Strategy PDF Preview

This map represents CDC’s largest funding categories for antibiotic resistance. It shows domestic, extramural funding that supports AR activities from multiple funding lines.

About CDC’s Work to Combat Antibiotic Resistance
With these investments, the Centers for Disease Control & Prevention (CDC), in partnership with health departments, academia, and healthcare, is transforming how the nation combats and slows antibiotic resistance at all levels, ensuring our ability to stand up a full, faster response to protect Americans from this threat.

These investments will better protect patients through:

  • Detection and Response
  • ✔  Rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread
  • ✔  Gold-standard lab capacity offered to all state and regional labs through CDC’s Antibiotic Resistance Laboratory Network

  • Prevention of Infections
  • ✔  Improve prevention of healthcare-associated infections, foodborne illness, and gonorrhea
  • ✔  Empowered networks for prevention across healthcare and communities for threats like Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), and “nightmare bacteria” carbapenem-resistant Enterobacteriaceae (CRE)
  • ✔  Insights for research innovation and better patient care

  • Improving Antibiotic Use
  • ✔  Ensure antibiotics work to protect patients from life-threatening infections or sepsis
  • ✔  Protect patients from unintended consequences associated with antibiotic use, including adverse drug events

These investments work toward meeting national goals to prevent drug-resistant infections as outlined in the National Action Plan for Combating Antibiotic-Resistant Bacteria.

Get Email Updates


To receive email updates about this page, enter your email address:


What's this? Submit

;